A Warning Letter Form FDA 483 “Inspectional Observations,” is a form used by the FDA to communicate concerns and document observations made by the FDA representative(s) during the inspection of a Life Sciences facility.No one can really quantify the cost of a warning letter, not even an average cost, due to an immense number of variables and intangibles associated with it. Life Sciences companies know that the impact and immeasurable costs to their company from a warning letter or 483 can be quite considerable. A company’s failure to comply with the CFR’s or GMP requirements and their inadequacies are made public record by the FDA. In addition, the idea of quantifying a warning letter from the FDA is nearly impossible as each company incurs different expenses and underlying abstract expenses. The severity of the warning also determines the amount of corrective action that needs to be taken or if a Quality Systems Improvement Initiative needs to be implemented.
Due to the many abstract variables and possible expenses, it is almost impossible to measure the cost to a company. This begs the question; is it important to try to financially quantify the impact of Warning Letter observations or is it more important to understand the types of observations that can impact a company?
As part of a two piece series, we are laying out those warning letter inspection observations that typically pose the most impact and costs to a company’s viability – both measurable and immeasurable.
With the large number of immeasurable costs, there are an equal number of measurable costs to receiving a warning letter. Join us for the 2nd part of this series as we delve into the top 5 measurable costs to a warning letter.
"*" indicates required fields